Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP7 | P09237 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | COMT | P21964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17273166 | 0.83 | CYP11B2 (0.31) | CYP11B2 | |
| SCHEMBL18680420 | 0.83 | MMP1 (0.33) | MMP1MMP7MMP9MMP8MMP13 | |
| SCHEMBL2117504 | 0.81 | CYP11B2 (0.30) | CYP11B2 | |
| Hydrochloric Acid SCHEMBL18662679 | 0.81 | MMP1 (0.32) | MMP1MMP7MMP9MMP8MMP13 | |
| SCHEMBL2608128 | 0.81 | MMP1 (0.37) | MMP1MMP7MMP9MMP8MMP13 | |
| SCHEMBL2606743 | 0.80 | MMP1 (0.36) | MMP1MMP7MMP9MMP8MMP13 | |
| SCHEMBL2117253 | 0.80 | MMP1 (0.36) | MMP1MMP7MMP9MMP8MMP13 | |
| SCHEMBL4756043 | 0.80 | MMP1 (0.36) | MMP1MMP7MMP9MMP8MMP13 | |
| Hydrochloric Acid SCHEMBL6990154 | 0.78 | MMP1 (0.35) | MMP1MMP7MMP9MMP8MMP13 | |
| SCHEMBL12949566 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | claimed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | claimed |
| EP-2134688-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | Apotex Technologies Inc. (CA) | 2009-12-23 | — | — | EP | claimed |
| WO-2008116301-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC. (CA) | 2008-10-02 | — | — | WO | claimed |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. | 2008-10-02 | — | — | US | claimed |
| US-9938240-B2 | Fluorinated derivatives of 3-hydroxypyridin-4-ones | APOTEX INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| US-9938240-B2 | Fluorinated derivatives of 3-hydroxypyridin-4-ones | APOTEX INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| US-9938240-B2 | Fluorinated derivatives of 3-hydroxypyridin-4-ones | APOTEX INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| US-20170088518-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | THE BANK OF NOVA SCOTIA (CA) | 2017-03-30 | — | — | US | disclosed |
| US-20170088518-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | THE BANK OF NOVA SCOTIA (CA) | 2017-03-30 | — | — | US | disclosed |
| US-20170088518-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | THE BANK OF NOVA SCOTIA (CA) | 2017-03-30 | — | — | US | disclosed |
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | disclosed |
| US-8673943-B2 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673943-B2 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| EP-2134688-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | Apotex Technologies Inc. (CA) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008116301-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116301-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | SLC40A1, TFRC, FECH | MMP1 4131/4885MMP7 3599/4885MMP9 4156/4885 |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | SLC40A1, TFRC, FECH | MMP1 4131/4885MMP7 3599/4885MMP9 4156/4885 |
| US-20170088518-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | FH, FECH, FPGS | MMP1 3660/4885MMP7 3242/4885MMP9 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.